Abstract:OBJECTIVE:To explore whether edaravone protects cells damage via mitogen-activated protein kinases (MAPKs) signal pathway, and which procedure of p38 be affected so as to add theories for AD pathogenesis and treatments. METHODS:According to different drugs treated, PC12 cells in vitro were divided into four groups. Negative control group: cells were treated with media alone. AD model group: cells were treated with 30 pmol/L Abeta(25-35). Inhibitor control group: cells were treated with 10 micromol/L SB203580 Cp38 mitogen-activated protein kinase (p38) inhibitor], 10 micromol/L SP600125 [c-Jun NH2 terminal kinase (JNK) inhibitor], or 10 micromol/L PD98059 extracelular signal regulated kinase (ERK) inhibitor]. Low-dose, middle-dose and high-dose edaravone group: cells plated for 24 hours treated with 30 micromol/L Abeta(25-35) and co-treated with 20, 40, 80 micromol/L edaravone 3 hours, respectively. The morphology of the treated cells were observed, the p-p38, p-JNK and p-ERK proteins in each group were tested by the Western blot. The p38 mRNA were tested in each group above (only add SB203580 10 micromol/L in third group) by the real time PCR. RESULTS:(1) The p-p38 protein was significantly increased in model control group compared with that in negative control group (P<0.05). The p-p38 protein in the inhibitor group and edaravone groups was decreased significantly (P<0.05) when compared with that in model control group. The p-p38 proteins were significantly increased in the three edaravone groups compared with that in inhibiter control group (P<0.05). The p-p38 protein in middle-dose edaravone group was decreased compared with that in low-dose edaravone group (P<0.05). There was no relationship in dose-dependent manner about edaravone. Compared with three edaravone groups, the p-p38 protein was lower than it in high-dose edaravone & inhibiter group (P<0.05). (2) The p-JNK protein was significantly increased in model control group compared with that in negative control group (P<0.05). The p-JNK protein in the inhibitor group was decreased compared with that in model control group (P<0.05). (3) No significantly difference of p-ERK protein concentration was observed in other groups when compared with that in negative control group (P>0.05 each). (4) Compared with negative control group, the p38 mRNA in model control group was significantly increased, and it was significantly decreased in inhibitor control group (P<0.05 each). In 40 micromol/L and 80 micromol/L edaravone groups, the p38 mRNA was significantly decreased compared with that in model control group, and it still was decreased compared with that in inhibitor control group (P<0.05). The p38 mRNA in 40 micromol/L edaravone group was the lowest among three edaravone groups, and it was obviously different from that in 20 micromol/L and 80 micromol/L edaravone groups (P<0.05). CONCLUSION:Abeta(25-35) could increase the p-p38 and p-JNK protein expression in cultured PC12 cells, but there was no obviously expression of p-ERK protein. These indicated that Abeta(25-35) might activate MAPKs signal pathway, especially p38 and JNK, and lead to PC12 cell damage. Edaravone could decrease p38 mRNA induced-Abeta(25-35), which indicated edaravone could protect PC12 cell damage via blocking p38 signal pathway in mRNA stage and protein stage simultaneously. Hence, it is promising that edaravone would be a new medicine for AD.

[The Effect of Edaravone on MAPKs Signal Pathway Associated with Abeta(25-35) Treatment in PC12 Cells].

Edaravone Ameliorates Oxidative Damage Associated with Aβ25-35 Treatment in PC12 Cells

Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

Protective Effect of Edaravone Against AÎ²25-35-Induced Mitochondrial Oxidative Damage in SH-SY5Y Cells

Protective Effects of Edaravone on Diffuse Brain Injury in Rats

Changes In Mitochondrial Dynamics During Amyloid Beta-Induced Pc12 Cell Apoptosis

Protective effect of EGb761 against Aβ1-42 -induced SHSY5Y cells injury and blood-brain barrier disruption via regulating Akt/Nrf2 signaling pathway

Edaravone Protects PC12 Cells from Ischemic-Like Injury Via Attenuating the Damage to Mitochondria

Edaravone Reduces Aβ-induced Oxidative Damage in SH-SY5Y Cells by Activating the Nrf2/ARE Signaling Pathway

Protective Effect of Edaravone Against Alzheimer's Disease-Relevant Insults in Neuroblastoma N2a Cells

[Protective effect of 1, 25(OH)_2D_3 on Aβ_(1-42)-induced pyrolysis in PC12 cells].

P4‐188: MAPKS SIGNALING PATHWAYS REGULATES THE ACTIVATION OF LRP1 RECEPTOR ON THE INTERNALIZATION OF Aβ <sub>1‐42</sub> AND Aβ <sub>1‐42</sub> ‐INDUCED NEUROTOXICITY

Significance of PI3K/Akt signal in apoptotic cells mimic Alzheimer's disease and the influence of edaravone

Edaravone Attenuates Brain Edema and Injury by Down-Regulating Expressions of P38 Mitogen-Activated Protein Kinase and Aquaporin-4 after Focal Cerebral Ischemia and Reperfusion in Mice

Effect of Edaravone on p-ERK1/2 protein and autophagy in the hippocampal neurons of SAH rats

Ginsenoside Rg1 promotes β‑amyloid peptide degradation through inhibition of the ERK/PPARγ phosphorylation pathway in an Alzheimer's disease neuronal model

Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells

Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2

Neuroprotective Effects of Emodin in Rat Cortical Neurons Against Β-Amyloid-induced Neurotoxicity

The Regulating Mechanism of Chrysophanol on Protein Level of CaM-CaMKIV to Protect PC12 Cells Against Aβ25-35-Induced Damage

Erythropoietin Prevents PC12 Cells from Beta-Amyloid-induced Apoptosis Via PI3K⁄Akt Pathway